Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities

Inga Buchmann, Donald Bunjes, Jörg Kotzerke, Hans Martin, Gerhard Glatting, Ulrike Seitz, Dirk Rattat, Andreas Buck, Hartmut Döhner, Sven N Reske

Fingerprint

Dive into the research topics of 'Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities'. Together they form a unique fingerprint.

Medicine & Life Sciences